28P - Sex differences in presentation, management and prognosis of Moroccan patients with non small cell lung carcinoma: A retrospective analysis of 224 c...

Date 17 April 2015
Event ELCC 2015
Session Poster lunch
Topics Non-Small-Cell Lung Cancer, Early Stage
Cancer Aetiology, Epidemiology, Prevention
Cancer in Special Situations
Presenter Lamiae Amaadour
Citation Annals of Oncology (2015) 26 (suppl_1): 6-9. 10.1093/annonc/mdv044
Authors L. Amaadour, L. Boudahna, Z. Benbrahim, S. Arifi, N. Mellas
  • Medical Oncology, University Hospital of Hassan II, 30000 - Fez/MA



Lung cancer is the most frequently diagnosed cancer in worldwide. However, since the beginning of the 1990s, its incidence is steadily increasing among women. The aim of our study was to assess differences in clinicopathological parameters and therapeutic outcomes of non small cell lung carcinoma between men and women.


From April 2007 to December 2012, 224 cases of non small cell lung carcinoma (NSCLC) were registered at the department of medical oncology of Hassan II University Hospital of Fez, Morocco, and reviewed retrospectively. Data regarding demographics, smoking, histology, treatment and survival were obtained.


There were 30 women and 194 men with NSCLC. The mean age was 58.26 years in women versus 57.64 years in men. Age < 50 years was more frequent in men than in women: 83% (n = 49) versus 17% (n = 10) p = 0.0001. Women were more frequently non-smokers than men (6.7% (n = 2) versus 88.1% (n = 171) p = 0,0001. Adenocarcinoma was the predominant pathological type both in men 60% and women 50%, whereas squamous carcinoma was more frequent in women than in men (36.6% versus 29.4%; p = 0.02). All women presented with metastatic disease at diagnosis; there were multiple metastases in 53.3% of women. However, 71.2% of men had stage IV disease (p = 0,0027). Thirty percent of women had a poor performance status (2/4 on the ECOG scale) versus thirty three percent of men. More women were treated by palliative platinum based chemotherapy (70% versus 63.4%; p = 0,01). A higher percentage of men received Navelbine monotherapy and best supportive care (13.3% and 6.6% versus 15.5% and 8.2% respectively). After a median follow-up of 6.5 months (range 1 to 15), overall survival and progression free survival were shorter in women than in their male counterparts (5 months versus 7.2 months: p = 0.003 and 4.6 months versus 6 months: p = 0,0025 respectively), independently of age, smoking habits, histological characteristics, and stage of disease.


These data demonstrate that important sex-associated differences exist in presentation and survival from lung cancer. Such differences should be considered when planning and analyzing clinical trials.


All authors have declared no conflicts of interest.